![](\"\/\/s.hotstocked.com\/hotstocked.com\/repository\/articles\/93\/93912\/pmcb_6m_450x350.png\")
Pharmacyte Biotech Inc (OTCMKTS:PMCB<\/a>) has had a hard time last month. After managing to keep its value around 7 cents per share for quite some time we saw the ticker begin to slide down the charts and lose a significant amount of altitude.<\/p>\n<\/p>\n
It then stabilized around the 5 cent per share mark and made several attempts at recovery, while the daily volumes increased. The company’s market cap has dropped below $50 million by now, which is rather decent for an OTC biotech. Meanwhile, the latest financial report, covering the quarterly period ended January 31, contains the following numbers of prime interest.<\/p>\n
<\/p>\n
- \n
- cash: $2.86 million<\/li>\n
- current assets: $2.87 million<\/li>\n
- current liabilities: $1.06 million<\/li>\n
- revenues: ZERO<\/li>\n
- net loss: $1.79 million<\/li>\n<\/ul>\n
<\/p>\n
Those numbers are fairly decent and seem enough to support the company through its operations for the time being. Still, PMCB<\/a><\/strong> isn’t very close to commercializing its product and there is still a lot hanging on the line.<\/p>\n
<\/p>\n
Two days ago PMCB<\/a><\/strong> announced that it will hold a shareholder conference on July 28, providing the latest information about the company’s clinical development program, as well as answering any shareholder and analyst submitted questions.<\/p>\n
<\/p>\n
This might be the reason for the recent positive movement of the company stock. Yesterday we saw PMCB<\/a><\/strong> gain another 6.20% in value and close at $0.058, while a total of 1.81 million traded shares generated $106 thousand in daily dollar volume.<\/p>\n
<\/p>\n